hla-a2 restricted synthetic tumor antigen
Biologicalexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2012 (NCT01795313)
Timeline
No events for the selected filters.
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- hla-a2 restricted synthetic tumor antigen
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01795313 | N/A | Aug 1, 2012 | National Cancer Institute (NCI), University of Pittsburgh |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2012 |
| University of Pittsburgh | Academic/Hospital | 1 | 1 | 1 | 2012 |
2 organizations
Page 1 / 1